-
1
-
-
0030956673
-
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
-
Ridker PM, Cushman M, Atampeer MJ, Tracy RP, Hennek-ens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336: 973-979.
-
(1997)
N Engl J Med
, vol.336
, pp. 973-979
-
-
Ridker, P.M.1
Cushman, M.2
Atampeer, M.J.3
Tracy, R.P.4
Hennekens, C.H.5
-
2
-
-
0034704893
-
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
-
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
-
(2000)
N Engl J Med
, vol.342
, pp. 836-843
-
-
Ridker, P.M.1
Hennekens, C.H.2
Buring, J.E.3
Rifai, N.4
-
3
-
-
1642277853
-
Creactive pro-tein modulates risk prediction based on the Framingham score: Implications for future risk assessment: Results from a large cohort study in southern Germany
-
Koenig W, Löwel H, Baumert J, Meisinger C. Creactive pro-tein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004;109: 1349-1353.
-
(2004)
Circulation
, vol.109
, pp. 1349-1353
-
-
Koenig, W.1
Löwel, H.2
Baumert, J.3
Meisinger, C.4
-
4
-
-
0030823183
-
IL-6 and APPs: Anti-inflamma-tory and immunosuppressive mediators
-
Tilg H, Dinarello CA, Mier J. IL-6 and APPs: anti-inflamma-tory and immunosuppressive mediators. Immunol Today 1997; 9:428-432.
-
(1997)
Immunol Today
, vol.9
, pp. 428-432
-
-
Tilg, H.1
Dinarello, C.A.2
Mier, J.3
-
5
-
-
28844475044
-
The novel role of Creactive protein in cardiovascular disease: Risk marker or pathogen
-
Wilson AM, Rhyan MC, Boyle AJ. The novel role of Creactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 2006;106:291-297.
-
(2006)
Int J Cardiol
, vol.106
, pp. 291-297
-
-
Wilson, A.M.1
Rhyan, M.C.2
Boyle, A.J.3
-
6
-
-
1842505521
-
Creactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases
-
Li JJ, Fang CH. Creactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 2004;62:499-506.
-
(2004)
Med Hypotheses
, vol.62
, pp. 499-506
-
-
Li, J.J.1
Fang, C.H.2
-
7
-
-
0033529379
-
Creactive protein as a cardiovascular risk factor: More than an epiphenomenon?
-
Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, Hack CE. Creactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999;100:96-102.
-
(1999)
Circulation
, vol.100
, pp. 96-102
-
-
Lagrand, W.K.1
Visser, C.A.2
Hermens, W.T.3
Niessen, H.W.4
Verheugt, F.W.5
Wolbink, G.J.6
Hack, C.E.7
-
8
-
-
0031454016
-
Prognostic influ-ence of increased fibrinogen and CRP levels in unstable coronary artery disease. Frisc Study Group. Fragmin during instability in coronary artery disease
-
Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influ-ence of increased fibrinogen and CRP levels in unstable coronary artery disease. Frisc Study Group. Fragmin during instability in coronary artery disease. Circulation 1997;96: 4204-4210.
-
(1997)
Circulation
, vol.96
, pp. 4204-4210
-
-
Toss, H.1
Lindahl, B.2
Siegbahn, A.3
Wallentin, L.4
-
9
-
-
0037454156
-
Troponin and Creactive protein have different relations to subsequent mortality and myocardial infarction after ACS: A GUSTO-IV substudy
-
GUSTO-IV-ACS Investigator
-
James SK, Armstrong P, Barnathan E, aliff R, Lindahl B, Sieg-bahn A, Simoons ML, Topol EJ, Venge P, Wallentin L, GUSTO-IV-ACS Investigator. Troponin and Creactive protein have different relations to subsequent mortality and myocardial infarction after ACS: a GUSTO-IV substudy. JAm Coll Cardiol 2003;41:916-924.
-
(2003)
J Am Coll Cardiol
, vol.41
, pp. 916-924
-
-
James, S.K.1
Armstrong, P.2
Barnathan, E.3
Aliff, R.4
Lindahl, B.5
Sieg-Bahn, A.6
Simoons, M.L.7
Topol, E.J.8
Venge, P.9
Wallentin, L.10
-
10
-
-
0029810933
-
Relation to Creactive protein and coronary heart disease in the MRFIT nested case-control study
-
Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation to Creactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996;144:537-547.
-
(1996)
Am J Epidemiol
, vol.144
, pp. 537-547
-
-
Kuller, L.H.1
Tracy, R.P.2
Shaten, J.3
Meilahn, E.N.4
-
11
-
-
10344231441
-
Inflammatory markers and the risk of coronary heart disease in men and women
-
Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351: 2599-2610.
-
(2004)
N Engl J Med
, vol.351
, pp. 2599-2610
-
-
Pai, J.K.1
Pischon, T.2
Ma, J.3
Manson, J.E.4
Hankinson, S.E.5
Joshipura, K.6
Curhan, G.C.7
Rifai, N.8
Cannuscio, C.C.9
Stampfer, M.J.10
Rimm, E.B.11
-
12
-
-
20444381235
-
Evaluation of Creactive protein measurement for assessing the risk and prognosis in ischemic stroke: A statement for health care pro-fessionals from the CRP Pooling Project members
-
Di Napoli M, Schwaninger M, Cappelli Ceccarelli E, Di Gianfilippo G, Donati C, Emsley HC, Forconi S, Hopkins SJ, Masotti L, Muir KW, Paciucci A, Papa F, Roncacci S, Sander D, Sander K, Smith CJ, Stefanini A, Weber D. Evaluation of Creactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care pro-fessionals from the CRP Pooling Project members. Stroke 2005;36:1316-1329.
-
(2005)
Stroke
, vol.36
, pp. 1316-1329
-
-
Di Napoli, M.1
Schwaninger, M.2
Cappelli Ceccarelli, E.3
Di Gianfilippo, G.4
Donati, C.5
Emsley, H.C.6
Forconi, S.7
Hopkins, S.J.8
Masotti, L.9
Muir, K.W.10
Paciucci, A.11
Papa, F.12
Roncacci, S.13
Sander, D.14
Sander, K.15
Smith, C.J.16
Stefanini, A.17
Weber, D.18
-
13
-
-
33645518246
-
Creactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: The EPIC-Norfolk prospective population study 1993-2003
-
Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, Peters RJ, Jukema JW, Day NE, Kastelein JJ, Khaw KT. Creactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: The EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006;187:415-422.
-
(2006)
Atherosclerosis
, vol.187
, pp. 415-422
-
-
Boekholdt, S.M.1
Hack, C.E.2
Sandhu, M.S.3
Luben, R.4
Bingham, S.A.5
Wareham, N.J.6
Peters, R.J.7
Jukema, J.W.8
Day, N.E.9
Kastelein, J.J.10
Khaw, K.T.11
-
14
-
-
34447637961
-
Comparison of a rapid platelet function assay-VerifyNow-Aspirin-with whole blood impedance aggregome-try for the detection of aspirin resistance
-
Dyszkiewicz-Korpanty AM, Kim A, Burner JD, Frenkel EP, Sarode R. Comparison of a rapid platelet function assay-VerifyNow-Aspirin-with whole blood impedance aggregome-try for the detection of aspirin resistance. Thromb Res 2007; 120:485-488.
-
(2007)
Thromb Res
, vol.120
, pp. 485-488
-
-
Dyszkiewicz-Korpanty, A.M.1
Kim, A.2
Burner, J.D.3
Frenkel, E.P.4
Sarode, R.5
-
15
-
-
33644983315
-
Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome
-
Chen YG, Xu F, Zhang Y, Ji QS, Sun Y, Lu RJ, Li RJ. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J 2006;119:32-36.
-
(2006)
Chin Med J
, vol.119
, pp. 32-36
-
-
Chen, Y.G.1
Xu, F.2
Zhang, Y.3
Ji, Q.S.4
Sun, Y.5
Lu, R.J.6
Li, R.J.7
-
16
-
-
19944430180
-
A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and Creactive protein following myocardial infarction: The CADET trial
-
Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM; CADET Study Investigators. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and Creactive protein following myocardial infarction: The CADET trial. J Thromb Haemost 2004;11:1934-1940.
-
(2004)
J Thromb Haemost
, vol.11
, pp. 1934-1940
-
-
Woodward, M.1
Lowe, G.D.2
Francis, L.M.3
Rumley, A.4
Cobbe, S.M.5
-
17
-
-
0033600543
-
Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
-
Ikonimidas I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793-798.
-
(1999)
Circulation
, vol.100
, pp. 793-798
-
-
Ikonimidas, I.1
Andreotti, F.2
Economou, E.3
Stefanadis, C.4
Toutouzas, P.5
Nihoyannopoulos, P.6
-
19
-
-
33846856622
-
Creactive protein (CRP)-lowering agents
-
Prasad K. Creactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006;24:33-50.
-
(2006)
Cardiovasc Drug Rev
, vol.24
, pp. 33-50
-
-
Prasad, K.1
-
20
-
-
0035312545
-
The effect of aspirin on Creactive protein as a marker of risk in unstable angina
-
Kennon S, Price CP, Mills PG, Ranjadayalan K, Cooper J, Clarke H, Timmis AD. The effect of aspirin on Creactive protein as a marker of risk in unstable angina. J Am Coll Cardiol 2001;37:1266-1270.
-
(2001)
J Am Coll Cardiol
, vol.37
, pp. 1266-1270
-
-
Kennon, S.1
Price, C.P.2
Mills, P.G.3
Ranjadayalan, K.4
Cooper, J.5
Clarke, H.6
Timmis, A.D.7
-
21
-
-
0035875796
-
2 concentrations: A placebo-controlled study using a highly sen-sitive Creactive protein assay
-
2 concentrations: A placebo-controlled study using a highly sen-sitive Creactive protein assay. J Am Coll Cardiol 2001;37: 2036-2041.
-
(2001)
J Am Coll Cardiol
, vol.37
, pp. 2036-2041
-
-
Feldman, M.1
Jialal, I.2
Devaraj, S.3
Cryer, B.4
-
22
-
-
0033958029
-
Effect of short-term aspirin use on Creactive protein
-
Feng D, Tracy RP, Lipinska I, Murillo J, McKenna C, Tofler GH. Effect of short-term aspirin use on Creactive protein. J Throm 2000;9:37-41.
-
(2000)
J Throm
, vol.9
, pp. 37-41
-
-
Feng, D.1
Tracy, R.P.2
Lipinska, I.3
Murillo, J.4
McKenna, C.5
Tofler, G.H.6
-
23
-
-
2442591457
-
Rofecoxib, a COX-2 inhibitor low-ers Creactive protein and interleukin-6 levels in patients with acute coronary syndromes
-
Monakier D, Mates M, Klutstein MW, Balkin JA, Rudensky B, Meerkin D, Tzivoni D. Rofecoxib, a COX-2 inhibitor low-ers Creactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest 2004;125:1610-1615.
-
(2004)
Chest
, vol.125
, pp. 1610-1615
-
-
Monakier, D.1
Mates, M.2
Klutstein, M.W.3
Balkin, J.A.4
Rudensky, B.5
Meerkin, D.6
Tzivoni, D.7
-
24
-
-
0037629751
-
Relationship between effects of statins, aspirin and angiotensin II modulators on high sensitive Creactive protein levels
-
Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high sensitive Creactive protein levels. Atherosclerosis 2003;169:155-158.
-
(2003)
Atherosclerosis
, vol.169
, pp. 155-158
-
-
Takeda, T.1
Hoshida, S.2
Nishino, M.3
Tanouchi, J.4
Otsu, K.5
Hori, M.6
-
25
-
-
0034669457
-
Cannon RO 3. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical manage-ment
-
Zanger D, Yang BK, Ardans J, Waclawiw MA, Csako G, Whli LM, Cannon RO 3. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical manage-ment. J Am Coll Cardiol 2000;36:1797-1802.
-
(2000)
J Am Coll Cardiol
, vol.36
, pp. 1797-1802
-
-
Zanger, D.1
Yang, B.K.2
Ardans, J.3
Waclawiw, M.A.4
Csako, G.5
Whli, L.M.6
-
26
-
-
31644451876
-
Lack of significant effect of low doses of aspirin on the concentrations of Creactive protein in a group of individuals with atherothrom-botic risk factors and vascular events
-
Rogowski O, Shapira I, Ben Assayang E, Bornstein NM, Tpker S, Melamed S, Shirom A, Berliner S. Lack of significant effect of low doses of aspirin on the concentrations of Creactive protein in a group of individuals with atherothrom-botic risk factors and vascular events. Blood Coagul Fibrinolysis 2006;17:19-22.
-
(2006)
Blood Coagul Fibrinolysis
, vol.17
, pp. 19-22
-
-
Rogowski, O.1
Shapira, I.2
Ben Assayang, E.3
Bornstein, N.M.4
Tpker, S.5
Melamed, S.6
Shirom, A.7
Berliner, S.8
-
27
-
-
31544464695
-
Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke
-
Zhao L, Gray L, Leonardi-Bee J, Weaver CS, Heptinstall S, Bath PM. Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets 2006;17: 100-104.
-
(2006)
Platelets
, vol.17
, pp. 100-104
-
-
Zhao, L.1
Gray, L.2
Leonardi-Bee, J.3
Weaver, C.S.4
Heptinstall, S.5
Bath, P.M.6
-
28
-
-
0025177196
-
Elevation of Creactive protein in "active" coronary artery disease
-
Berk BC, Weintraub WS, Alexander RW. Elevation of Creactive protein in "active" coronary artery disease. Am J Cardiol 1990;65:168-172.
-
(1990)
Am J Cardiol
, vol.65
, pp. 168-172
-
-
Berk, B.C.1
Weintraub, W.S.2
Alexander, R.W.3
-
29
-
-
12144290962
-
Effects of angiotensin-converting enzyme inhibitors, beta-blockers, statins, and aspirin on C-rective pro-tein levels in outpatients with heart failure
-
Joynt KE, Gattis WA, Hasselbladf V, Fuzaylov SY, Serebru-any VL, Gurbel PA, Gaulden LH, Felker GM, Whellan DJ, O'Conner CM. Effects of angiotensin-converting enzyme inhibitors, beta-blockers, statins, and aspirin on C-rective pro-tein levels in outpatients with heart failure. Am J Cardiol 2004;93:783-785.
-
(2004)
Am J Cardiol
, vol.93
, pp. 783-785
-
-
Joynt, K.E.1
Gattis, W.A.2
Hasselbladf, V.3
Fuzaylov, S.Y.4
Serebru-Any, V.L.5
Gurbel, P.A.6
Gaulden, L.H.7
Felker, G.M.8
Whellan, D.J.9
O'Conner, C.M.10
-
31
-
-
0035963529
-
Air force/Texas coronary atherosclerosis pre-vention study investigators. Measurement of Creactive pro-tein for the targeting of statin therapy in the primary prevention of acute coronary events
-
Ridker PM, Rifai, N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr. Air force/Texas coronary atherosclerosis pre-vention study investigators. Measurement of Creactive pro-tein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344: 1959-1965.
-
(2001)
N Engl J Med
, vol.344
, pp. 1959-1965
-
-
Ridker, P.M.1
Rifai, N.2
Clearfield, M.3
Downs, J.R.4
Weis, S.E.5
Miles, J.S.6
Gotto Jr., A.M.7
-
32
-
-
0036558577
-
Short-term effects of atorvastatin on Creactive protein
-
Riesen WF, Engler H, Risch M, Korte W, Noseda G. Short-term effects of atorvastatin on Creactive protein. Eur Heart J 2002;23:794-799.
-
(2002)
Eur Heart J
, vol.23
, pp. 794-799
-
-
Riesen, W.F.1
Engler, H.2
Risch, M.3
Korte, W.4
Noseda, G.5
-
33
-
-
0038244833
-
Atorvastain affects Creactive protein levels in patients with coronary artery disease
-
Karaca I, Ilkay,E, Akbulut M, Yavuzkir M, Pekdmir M, Akbulut H, Arslan N. Atorvastain affects Creactive protein levels in patients with coronary artery disease. Curr Med Res Opin 2003;19:187-191.
-
(2003)
Curr Med Res Opin
, vol.19
, pp. 187-191
-
-
Karaca, I.1
Ilkay, E.2
Akbulut, M.3
Yavuzkir, M.4
Pekdmir, M.5
Akbulut, H.6
Arslan, N.7
-
34
-
-
0037313037
-
Effect of atorvastatin and pravastatin on serum Creactive pro-tein
-
Kent SM, Flatherty PJ, Coyle LC, Markwood TT, Taylor AJ. Effect of atorvastatin and pravastatin on serum Creactive pro-tein. Am Heart J 2003;145:P1-P4.
-
(2003)
Am Heart J
, vol.145
-
-
Kent, S.M.1
Flatherty, P.J.2
Coyle, L.C.3
Markwood, T.T.4
Taylor, A.J.5
-
35
-
-
0035806626
-
Effect of statin therapy on Creactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE), a randomized trial and cohort study
-
Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on Creactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE), a randomized trial and cohort study. J Am Med Assoc 2001;286:64-70.
-
(2001)
J Am Med Assoc
, vol.286
, pp. 64-70
-
-
Albert, M.A.1
Danielson, E.2
Rifai, N.3
Ridker, P.M.4
-
36
-
-
19944429519
-
Statin therapy, LDL cholesterol, Creactive protein, and coronary artery disease
-
REVERSAL investigators
-
Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tasi J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P, REVERSAL investigators. Statin therapy, LDL cholesterol, Creactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
-
(2005)
N Engl J Med
, vol.352
, pp. 29-38
-
-
Nissen, S.E.1
Tuzcu, E.M.2
Schoenhagen, P.3
Crowe, T.4
Sasiela, W.J.5
Tasi, J.6
Orazem, J.7
Magorien, R.D.8
O'Shaughnessy, C.9
Ganz, P.10
-
37
-
-
0037212882
-
Strong decrease of high sensitivity Creactive protein with high-dose atorvastatin in patients with type-2 diabetes mellitus
-
DALI-study Group
-
Van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C; DALI-study Group. Strong decrease of high sensitivity Creactive protein with high-dose atorvastatin in patients with type-2 diabetes mellitus. Atherosclerosis 2003;166:129-135.
-
(2003)
Atherosclerosis
, vol.166
, pp. 129-135
-
-
Van De Ree, M.A.1
Huisman, M.V.2
Princen, H.M.3
Meinders, A.E.4
Kluft, C.5
-
38
-
-
28444451901
-
Atorvastatin lowers plasma low-density lipo-protein cholesterol and Creactive protein in Japanese type 2 diabetic patients
-
Yamada S, Yanagawa T, Sasamoto K, Araki A, Miyao M, Yamanouchi T. Atorvastatin lowers plasma low-density lipo-protein cholesterol and Creactive protein in Japanese type 2 diabetic patients. Metabolism 2006;55:67-71.
-
(2006)
Metabolism
, vol.55
, pp. 67-71
-
-
Yamada, S.1
Yanagawa, T.2
Sasamoto, K.3
Araki, A.4
Miyao, M.5
Yamanouchi, T.6
-
39
-
-
11344279659
-
Creactive protein levles and outcome after statin therapy
-
PROVE IT-TIMI 22 Investigators
-
Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, PROVE IT-TIMI 22 Investigators. Creactive protein levles and outcome after statin therapy. N Engl J Med 2005;352:20-28.
-
(2005)
N Engl J Med
, vol.352
, pp. 20-28
-
-
Ridker, P.M.1
Cannon, C.P.2
Morrow, D.3
Rifai, N.4
Rose, L.M.5
McCabe, C.H.6
Pfeffer, M.A.7
Braunwald, E.8
-
40
-
-
20044367345
-
Aggressive antihypertensive therapy based on hydrochlorothi-azide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: Effects on albumin excretion, endothelial function and inflammation in double-blind, ran-domized clinical trial
-
Schram MT, van Ittersum FJ, Spoelstra-de Man A, van Dijk RA, Schalkwijk CG, Ijzerman RG, Twisk JW, Stehouwer CD. Aggressive antihypertensive therapy based on hydrochlorothi-azide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: Effects on albumin excretion, endothelial function and inflammation in double-blind, ran-domized clinical trial. J Hum Hypertens 2005;19:429-437.
-
(2005)
J Hum Hypertens
, vol.19
, pp. 429-437
-
-
Schram, M.T.1
Van Ittersum, F.J.2
Spoelstra-De Man, A.3
Van Dijk, R.A.4
Schalkwijk, C.G.5
Ijzerman, R.G.6
Twisk, J.W.7
Stehouwer, C.D.8
-
41
-
-
21144444790
-
Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity Creactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus
-
Koulouris S, Symeonides P, Triantafyllou K, Ioannidis G, Katostaras T, El-Ali M, Theodoridis T, Vratsista E, Thalassi-nos N, Kokkinou V, Nanas I, Stamatelopoulos S, Toutouzas P. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity Creactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol 2005;95:1386-1388.
-
(2005)
Am J Cardiol
, vol.95
, pp. 1386-1388
-
-
Koulouris, S.1
Symeonides, P.2
Triantafyllou, K.3
Ioannidis, G.4
Katostaras, T.5
El-Ali, M.6
Theodoridis, T.7
Vratsista, E.8
Thalassi-Nos, N.9
Kokkinou, V.10
Nanas, I.11
Stamatelopoulos, S.12
Toutouzas, P.13
-
42
-
-
2542475889
-
Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy
-
Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004;43:2116-2123.
-
(2004)
J Am Coll Cardiol
, vol.43
, pp. 2116-2123
-
-
Yasunari, K.1
Maeda, K.2
Watanabe, T.3
Nakamura, M.4
Yoshikawa, J.5
Asada, A.6
-
43
-
-
0037192336
-
Fosinopril versus amlodipine comparative treatments study: A randomized trial to assess effects on plas-minogen activator inhibitor-1
-
Pahor M, Franse LV, Deitcher SR, Cushman WC, Johnson KC, Shorr RI, Kottke-Marchant K, Tracy RP, Somes GW, Applegate WB. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plas-minogen activator inhibitor-1. Circulation 2002;105:457-461.
-
(2002)
Circulation
, vol.105
, pp. 457-461
-
-
Pahor, M.1
Franse, L.V.2
Deitcher, S.R.3
Cushman, W.C.4
Johnson, K.C.5
Shorr, R.I.6
Kottke-Marchant, K.7
Tracy, R.P.8
Somes, G.W.9
Applegate, W.B.10
-
44
-
-
18244384044
-
Carvedilol reduces plasma 8-hydroxy-2-deoxygua-nosine in mild to moderate hypertension: A pilot study
-
Lee J, Lee M, Kim JU, Song KI, Choi YS, Cheong SS. Carvedilol reduces plasma 8-hydroxy-2-deoxygua-nosine in mild to moderate hypertension: A pilot study. Hypertension 2005;45:986-990.
-
(2005)
Hypertension
, vol.45
, pp. 986-990
-
-
Lee, J.1
Lee, M.2
Kim, J.U.3
Song, K.I.4
Choi, Y.S.5
Cheong, S.S.6
|